GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zomedica Corp (AMEX:ZOM) » Definitions » Change In Payables And Accrued Expense

Zomedica (Zomedica) Change In Payables And Accrued Expense : $-1.64 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Zomedica Change In Payables And Accrued Expense?

Zomedica's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $-1.13 Mil. It means Zomedica's Accounts Payable & Accrued Expense declined by $1.13 Mil from Dec. 2023 to Mar. 2024 .

Zomedica's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $0.26 Mil. It means Zomedica's Accounts Payable & Accrued Expense increased by $0.26 Mil from Dec. 2022 to Dec. 2023 .

Zomedica Change In Payables And Accrued Expense Historical Data

The historical data trend for Zomedica's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zomedica Change In Payables And Accrued Expense Chart

Zomedica Annual Data
Trend Feb14 Feb15 Feb16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.29 -0.84 1.61 3.40 0.26

Zomedica Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 -1.42 -0.51 1.42 -1.13

Zomedica Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zomedica Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Zomedica's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Zomedica (Zomedica) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zomedica Corp (AMEX:ZOM) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
OPTN MRMD ALIM ELTP EGRX CHHE EBS ASRT AQST ETON ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
100 Phoenix Drive, Suite 125, Ann Arbor, MI, USA, 48108
Website
https://www.zomedica.com
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is currently focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments: Diagnostic & Therapeutics. It earns the majority of revenue from the therapeutics segment.
Executives
Johnny D Powers director C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Heaton Larry C Ii officer: President C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Russell Kevin Klass officer: Vice President of Sales C/O ZOMEDICA CORP, PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Peter Donato officer: Chief Financial Officer 9172 ETON AVENUE, CHATSWORTH CA 91311
Pamela Nichols director 14841 EAST WILDCAT DR., SCOTTSDALE AZ 85262
Karen Dehaan-fullerton officer: Chief Counsel and Secretary C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Anthony K Blair officer: Chief Operating Officer NEOPROBE CORPORATION, 425 METRO PLACE NORTH #300, DUBLIN OH 43017
Adrian Lock officer: VP and General Manager C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Sean Whelan director C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Robert Cohen officer: Interim CEO C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Ann Cotter officer: Chief Financial Officer & Sec. C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108
Stephanie Morley officer: COO & VP of Product Dev C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Christopher Ross Macleod director C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Christopher Wolfenberg director C/O ZOMEDICA PHARMACEUTICALS CORP, 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108
Gerald Jr Solensky director, 10 percent owner, officer: President and CEO C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 190, ANN ARBOR MI 48108